| Tuberculosis Research and Epidemiology | Lifetime | 3 | GB 1 | 99.96 |
| Diagnosis and treatment of tuberculosis | Lifetime | 1 | GB 1 | 99.91 |
| COVID-19 Clinical Research Studies | Lifetime | 8 | GB 2 | 99.92 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 4 | GB 2 | 99.90 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 15 | GB 1 | 99.88 |
| Infectious Diseases and Tuberculosis | Lifetime | 8 | GB 1 | 99.83 |
| Mycobacterium research and diagnosis | Lifetime | 17 | GB 2 | 99.81 |
| Global Health and Surgery | Lifetime | 5 | GB 1 | 99.42 |
| COVID-19 epidemiological studies | Lifetime | 37 | GB 11 | 99.50 |
| Viral Infections and Outbreaks Research | Lifetime | 38 | GB 1 | 99.45 |
| Pneumonia and Respiratory Infections | Lifetime | 116 | GB 17 | 99.47 |
| Travel-related health issues | Lifetime | 14 | GB 1 | 98.94 |
| HIV/AIDS Impact and Responses | Lifetime | 25 | GB 6 | 98.97 |
| Zoonotic diseases and public health | Lifetime | 45 | GB 10 | 99.08 |
| COVID-19 and healthcare impacts | Lifetime | 137 | GB 32 | 97.49 |
| Viral Infections and Vectors | Lifetime | 948 | GB 68 | 97.38 |
| Immune responses and vaccinations | Lifetime | 130 | GB 19 | 95.27 |
| Long-Term Effects of COVID-19 | Lifetime | 964 | GB 104 | 94.29 |
| Bacillus and Francisella bacterial research | Lifetime | 800 | GB 51 | 90.18 |
| Infection Control and Ventilation | Lifetime | 685 | GB 53 | 89.36 |
| Poxvirus research and outbreaks | Lifetime | 806 | GB 79 | 87.71 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 8 | GB 1 | 99.48 |
| COVID-19 Clinical Research Studies | 2021-2025 | 199 | GB 22 | 98.96 |
| Viral Infections and Outbreaks Research | 2021-2025 | 26 | GB 3 | 97.89 |
| Zoonotic diseases and public health | 2021-2025 | 19 | GB 3 | 98.10 |
| Viral Infections and Vectors | 2021-2025 | 88 | GB 5 | 97.67 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 363 | GB 35 | 98.43 |
| COVID-19 and healthcare impacts | 2021-2025 | 212 | GB 51 | 95.91 |
| Viral gastroenteritis research and epidemiology | 2021-2025 | 140 | GB 5 | 96.56 |
| COVID-19 epidemiological studies | 2021-2025 | 254 | GB 36 | 96.47 |
| Travel-related health issues | 2021-2025 | 14 | GB 1 | 95.82 |
| Long-Term Effects of COVID-19 | 2021-2025 | 884 | GB 118 | 93.50 |
| HIV/AIDS Impact and Responses | 2021-2025 | 45 | GB 3 | 89.05 |
| Mosquito-borne diseases and control | 2021-2025 | 630 | GB 57 | 92.83 |
| Bacillus and Francisella bacterial research | 2021-2025 | 112 | GB 8 | 90.63 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 235 | GB 20 | 90.29 |
| Poxvirus research and outbreaks | 2021-2025 | 119 | GB 7 | 91.20 |
| Animal Virus Infections Studies | 2021-2025 | 577 | GB 16 | 89.00 |
| Vaccine Coverage and Hesitancy | 2021-2025 | 983 | GB 111 | 90.03 |
| Immune responses and vaccinations | 2021-2025 | 129 | GB 6 | 85.88 |
| Pneumonia and Respiratory Infections | 2021-2025 | 775 | GB 73 | 88.29 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 234 | GB 21 | 83.52 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 516 | GB 19 | 74.75 |
| Global Health and Surgery | 2021-2025 | 908 | GB 108 | 60.07 |
| Autopsy Techniques and Outcomes | 2021-2025 | 620 | GB 41 | 57.92 |
